Author: Groeneveld, Geert H; van der Reyden, Tanny J; Joosten, Simone A; Bootsma, Hester J; Cobbaert, Christa M; de Vries, Jutte J C; Kuijper, Ed J; van Dissel, Jaap T
Title: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial Document date: 2019_5_18
ID: 19ueli6e_59
Snippet: A large randomized trial of patients with Gram-positive Staphylococcus aureus bacteraemia showed no adjunctive clinical benefit of rifampicin over standard (most often flucloxacillin) antibiotic treatment. 37 Long-term endpoints in that trial were used, making comparison with our short-term outcome measures difficult......
Document: A large randomized trial of patients with Gram-positive Staphylococcus aureus bacteraemia showed no adjunctive clinical benefit of rifampicin over standard (most often flucloxacillin) antibiotic treatment. 37 Long-term endpoints in that trial were used, making comparison with our short-term outcome measures difficult.
Search related documents:
Co phrase search for related documents- antibiotic treatment and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibiotic treatment and outcome measure: 1, 2, 3, 4, 5, 6
- antibiotic treatment and randomized trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- antibiotic treatment and short term: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antibiotic treatment and Staphylococcus aureus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibiotic treatment and Staphylococcus aureus bacteraemia: 1
- clinical benefit and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical benefit and outcome measure: 1, 2, 3, 4, 5, 6, 7
- clinical benefit and randomized trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical benefit and short term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- clinical benefit and Staphylococcus aureus: 1, 2, 3
- clinical benefit and Staphylococcus aureus bacteraemia: 1
- flucloxacillin standard and Staphylococcus aureus: 1
- long term and outcome measure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term and randomized trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term and short term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term and short term outcome measure: 1
- long term and Staphylococcus aureus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term endpoint and short term: 1
Co phrase search for related documents, hyperlinks ordered by date